Foresee Pharmaceuticals (逸達) announced on the 8th that its US subsidiary, Foresee Pharmaceuticals USA Inc., has signed an exclusive global license agreement with Primevera Therapeutics, LLC for its matrix metalloproteinase-12 (MMP-12) inhibitor series.

Financial and Strategic Terms:

• Deal Structure: Foresee receives a US$10 million upfront payment and is eligible for up to US$574.5 million in milestones and royalties. Additionally, Foresee will hold a 19% equity stake in Primevera.
• Portfolio Scope: The deal covers FP-025, FP-020, and third-generation inhibitors currently in the drug discovery phase.
• Corporate Synergy: Primevera is a newly formed Delaware entity by QPS, a related party to Foresee. Primevera will assume all future R&D expenses for the MMP-12 portfolio.

Operational Pivot: Chairman Dr. Ben Chien stated that this move allows Foresee to optimize resource allocation toward its Stabilized Injectable Formulation (SIF) platform. The company is prioritizing its lead product, CAMCEVI (FP-001):

• Central Precocious Puberty (CPP): Following successful Phase 3 results, an NDA submission to the US FDA is planned for mid-2026.
• Commercial Expansion: The 6-month depot is performing steadily in the US, with the higher-potential 3-month depot expected to launch in Q4 2026.

Resource: 逸達與美國Primevera簽署MMP-12抑制劑授權協議 可獲184億權利金